Advertisement

Topics

Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia

07:00 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Therachon AG, a biotechnology company focused on rare genetic diseases, announced today that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to TA-46 for t...

Other Sources for this Article

Pure Communications, Inc.
Katie Engleman, 919-333-7722
kengleman@purecommunications.com

NEXT ARTICLE

More From BioPortfolio on "Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...